Researchers Report Encouraging Results From Experimental Eye Stem Cell Therapy
Scientists at Massachusetts Eye and Ear, part of the Mass General Brigham health system, have reported promising findings from an early-stage clinical trial evaluating an experimental stem cell treatment for severe corneal injuries.
The study, published in Nature Communications, investigated whether patients’ own limbal stem cells could be used to rebuild the surface of the eye after injuries that damaged the cornea.
Although the treatment remains experimental and is not yet widely available, researchers say the results represent an important step in the development of regenerative therapies for certain forms of vision loss.
Understanding Limbal Stem Cell Deficiency
The cornea is the transparent front surface of the eye that helps focus light for clear vision.
At the edge of the cornea is a narrow region known as the limbus, which contains limbal epithelial stem cells. These cells continuously regenerate the corneal surface throughout life.
When these stem cells are destroyed by chemical burns, thermal injuries, infections, or other severe trauma, the eye may develop limbal stem cell deficiency (LSCD). This condition can lead to persistent pain, scarring, inflammation, and significant vision impairment.
Traditional corneal transplantation alone may not be effective in these patients because the damaged eye no longer has enough healthy stem cells to maintain the transplanted tissue.
How the CALEC Procedure Works
The experimental treatment, known as Cultivated Autologous Limbal Epithelial Cell (CALEC) transplantation, uses the patient’s own healthy stem cells.
The procedure generally involves three steps:
- Doctors collect a very small sample of limbal stem cells from the patient’s unaffected eye.
- The cells are expanded in a specialized laboratory over several weeks to create a larger tissue graft.
- Surgeons transplant the laboratory-grown tissue onto the damaged eye after removing scarred surface tissue.
Because the cells come from the patient’s own body, the risk of immune rejection is lower than with donor tissue.
Clinical Trial Results
The Phase 1/2 clinical study included 14 patients with severe limbal stem cell deficiency affecting one eye.
According to the researchers:
- Most treated eyes achieved successful restoration of the corneal surface.
- Participants experienced improvements in corneal health during follow-up.
- Many patients also showed improvements in vision after treatment.
The researchers emphasized that these findings are based on a small early-stage clinical trial and require confirmation in larger studies.
Current Limitations
While the results are encouraging, CALEC remains an investigational therapy.
The procedure currently requires one healthy eye because stem cells are collected from the patient’s own limbus.
Researchers are also studying donor-based approaches that may one day help patients with injuries affecting both eyes.
Additional clinical trials will be needed to further evaluate long-term safety, effectiveness, and eligibility before the treatment can be considered for broader clinical use.
What This Could Mean for Patients
Experts say regenerative medicine continues to expand treatment possibilities for conditions that previously had limited options.
If future studies confirm these early findings, stem cell therapies may provide new treatment approaches for selected patients with severe corneal surface disease.
However, physicians caution that patients should continue to consult qualified ophthalmologists about currently approved treatment options while research continues.
The research team plans to continue evaluating the therapy through larger clinical studies designed to confirm the safety and effectiveness of the procedure.
Regulatory review would be required before the treatment becomes available for routine clinical care.
The CALEC study represents an important advance in regenerative eye research and highlights the potential of using a patient’s own stem cells to repair damaged corneal tissue.
Although the therapy remains experimental, the early clinical results provide encouraging evidence that stem cell-based treatments may expand future options for people living with severe corneal injuries.
Photo by Antonika Chanel on Unsplash
About Wellcore Weekly: Wellcore Weekly covers health, wellness, nutrition, sleep, fitness, and medical research with timely, easy-to-understand updates for everyday readers.
